FIELD: pharmaceutical industry, in particular high quality insulin drug of durable action.
SUBSTANCE: claimed method includes providing of human insulin ester by transpeptization of porcine insulin at molar excess of threonine di-tert-butyl ester in aqueous/organic medium in presence of trypsin; acidifying for reaction inhibiting; chromatography purifying of obtained human insulin; deblocking of protective groups with trifluotoacetic acid and purifying of obtained crude human insulin; with subsequent dissolution in diluted acid, addition of acid solutions of zinc ions and protamine sulfate, mixing with buffered solution of m-cresol, phenol and glycerol; and solution conditioning to form crystals. Weight ratio of trypsin and porcine insulin is 1:300-1000. Before acidifying of reaction media reaction is additionally inhibited by mixture dilution with water by 2-3 times. Human insulin ester is purified using HPLC followed by deposition of ester derivatives fractions in presence of zinc ions and protective group deblocking to produce crystals of crude human insulin, which is purified again by HPLC, wherein both purifying processes are carried out using sorbent DIASOGEL ODS (C18) with particle size of 15 mum and pore size of 120 A as stationary phase, and as mobile phase in the first step 0.06 M-glycine HCl buffer, containing 0.015 M of ammonium sulfate and 20-30 % of propan-2-ol, having pH 2.5 is used, and in the second one 0.05 M acetate buffer containing 10-20 % of propan-2-ol with pH 2.5 is used. Then purified human insulin crystals are step-by-step dissolved in diluted acid to obtain fine dispersed suspension of insulin crystals in water; then diluted acid is added thereto, and mixture obtained after blending with buffered solution of cresol, phenol and glycerol, is held at 18-21°C for 20-22 h.
EFFECT: effective and economical method for insulin production with increased yield and purity; insulin of durable action and low immunological properties.
12 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREPARING HUMAN INSULIN COMBINED PREPARATION | 2002 |
|
RU2261108C2 |
METHOD FOR PREPARING READY MEDICINAL FORMULATION OF INSULIN WITH SHORT EFFECT | 2002 |
|
RU2261107C2 |
HUMAN INSULIN DRUG OF DURABLE ACTION | 2003 |
|
RU2252753C2 |
HUMAN INSULIN DRUG OF SHORT ACTION | 2003 |
|
RU2252752C2 |
METHOD FOR PRODUCTION OF SEMISYNTHETIC HUMAN INSULIN | 2002 |
|
RU2252225C2 |
METHOD OF HIGHLY PURIFIED MONOCOMPONENT INSULIN PREPARING | 2000 |
|
RU2186581C2 |
METHOD FOR PREPARING HIGH-PURITY CRYSTALLINE INSULIN OF ANY ORIGIN | 2011 |
|
RU2453331C1 |
PHARMACEUTICAL PREPARATION CONTAINING GROWTH HORMONE OR GROWTH HORMONE DERIVATIVE AND HISTIDINE OR HISTIDINE DERIVATIVE, A PREPARATION THAT IS GROWTH HORMONE CRYSTALS CONTAINING HISTIDINE OR HISTIDINE DERIVATIVE AND A METHOD OF PREPARING GROWTH HORMONE CRYSTALS AND HISTIDINE OR HISTIDINE DERIVATIVE | 1992 |
|
RU2122426C1 |
METHOD OF PRODUCTION, USE AND COMPOSITION OF MINOR SPHERICAL PARTICLES PRODUCED IN CONTROLLED PHASE SEPARATION | 2004 |
|
RU2426590C2 |
PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
Authors
Dates
2005-05-27—Published
2002-12-26—Filed